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1. Stimulation of cardiomyocyte hypertrophy
In vivo cardiac hypertrophy is a slow process in which the
myocytes increase in size in response to increased workload
due to either an increase in hemodynamic load or to a loss of
functional myocytes. Although the mechanical load has long
been recognized as the most powerful hypertrophic stimulus,
its signal transmission from the cell surface to the nuclear
transcription activities has largely remained elusive. Apart
from the mechanical stress, the hypertrophic reaction is
monitored by a large number of neurotransmitters, hor-
mones, growth factors, and cell mediators that under normal
conditions stay in balance within a limited range of variation
[1]. However, under chronic mechanical overload, ischemic
conditions, or late-onset genetic diseases, all of which may
be accompanied by inflammation, the ensemble of these
factors becomes imbalanced, affecting the gene expression
program and thus triggering the remodeling process that
eventually leads to fatal cardiac dysfunction. The signaling
cascades involved in the hypertrophic reaction include the
mitogen-activated protein kinase (MAPK) pathway with its
four branches (i) ERK1/2 (extracellular signal-regulated
kinases), (ii) p38 MAPK, (iii) JNK (c-Jun N-terminal kinase)
and (iv) BMK1 (big MAPK1=ERK5); furthermore, the
cAMP-dependent PKA pathway, the PI3K–PKB/Akt path-
way, the calcineurin—NFAT–MEF2 pathway, and the JAK/
Stat (Janus kinase/signal transducer and activator of
transcription) pathway are also involved [1]. The latter
JAK/Stat signaling cascade is typically activated during
inflammation by the interleukin-6-related cytokines
(IL6, cardiotrophin-1=CT1, and the leukemia inhibitory
factor=LIF), which are potent inducers of cardiac hypertro-
phy [2]. In addition, prostaglandin-E2 (PGE2) has been
reported to be involved in cardiomyocyte hypertrophy,
specifically by stimulation of its G-protein-coupled receptor
subtype EP4 involving transactivation of the epidermal
growth factor receptor (EGFR) and ERK1/2 [3,4] (Fig. 1).
PGE2 is synthesized by an enzyme cascade localized to the
nuclear envelope comprising phospholipase-A2 (PLA2),
cyclooxygenase-2 (COX2), and prostaglandin-E synthases
(PGES). PGE2 may act extracellularly and intracellularly
since its EP4 receptor is localized to the sarcolemma as well
as to the nuclear envelope [5].
2. Stat3 here — who's knocking?
The group of Ursula Lang elegantly shows in this issue of
the Journal (Frias et al., ref. [6]) that 1 μM PGE2 induces an
increase in cell size and stimulates protein synthesis in
spontaneously beating ventricular neonatal rat cardiomyo-
cytes (VNRC) in culture by signaling primarily via its EP4
receptor subtype involving successive phosphorylation of
MEK1/2 (mitogen-activated ERK activating kinases) and
ERK1/2 and of Stat3 at Tyr705 in the C-terminal
transactivation domain. Upon stimulation with 100 nM
PGE2 the degree of phosphorylation of MEK1/2 and ERK1/
2 reaches a transient maximum after 2–5 min while in Stat3
the maximum occurs only after 60 min. Inhibition of the
ERK1/2 pathway by U0126 (inhibiting both MEK1 and
MEK2) and application of the tyrosine kinase inhibitor
genistein both abolished PGE2-induced tyrosine phosphor-
ylation of Stat3 and its binding to the sis-inducible element in
the promoter region of the c-fos gene as assessed by
electrophoretic mobility shift assay. Contributions by p38
MAPK or PKA signaling could be excluded by using various
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inhibitors and activators of these pathways. Furthermore,
transfection of VNRC with small interfering RNA (siRNA)
specifically targeting the rat Stat3 reduced expression of the
latter by ∼70% and inhibited the hypertrophic reaction. The
requirement of 1 μM PGE2 for eliciting the hypertrophic
reaction observed in VNRC seems rather high in view of the
∼10,000-fold lower physiological plasma levels (60–
110 pM) in the rat [7]. The authors may argue, however,
that the intracellular biosynthesis of PGE2 could lead to
significantly higher local concentrations than that found
extracellularly in the plasma. Blockade of the delayed
Tyr705 phosphorylation of Stat3 by the transcription
inhibitor actinomycin-D as well as by the translation inhib-
itor cycloheximide [6] suggests that in VNRC stimulated by
PGE2 the phosphorylation of Stat3 at Tyr705 is not the
direct target of ERK1/2 although Ser727 of Stat3 was
shown to serve as substrate for ERK1/2 in other cell sys-
tems [2]. Bearing in mind that genistein abolishes Stat3
phosphorylation, it seems that an as yet undefined
intermediate tyrosine kinase may originate from de novo
protein synthesis. Obviously, the PGE2 signaling in VNRC
between EP4 and MEK1/2 as well as between ERK1/2 and
Stat3 requires further exploration [6]. Here we tentatively
review possible candidates involved in knocking on
Stats' door.
3. The JAK/Stat pathway
Most hypertrophic stimuli such as stretch, angiotensin-II
(AngII), IL6, CT1, and LIF activate the latent cytoplasmic
transcription factors Stat1 and Stat3. Downregulation of
Stat3 is associated with end-stage heart failure, and its
activation promotes cardiomyocyte survival and hypertro-
phy, while Stat1 correlates with pro-inflammatory responses
and apoptosis [8,9]. In the canonical JAK/Stat signaling
pathway, binding of the IL6-related cytokines induces
dimerization of their receptors (gp130 and LIFR) and
tyrosine phosphorylation in the cytoplasmic domain by the
receptor-associated tyrosine JAK1/2 kinases for recruitment
of specific Stats from the cytoplasm. After phosphorylation
of Stat1 at Tyr701 and Stat3 at Tyr705, they dimerize (homo-
or heterodimers) and translocate to the cell nucleus where
they associate with the transcription machinery (Fig. 1). For
full transcriptional activity Stat1 and Stat3 require additional
phosphorylation of Ser727 in the transactivation domain,
which represents a recognition site for ERK1/2, p38 MAPK,
and other yet to be defined serine kinases [12]. In isolated
mouse hearts rapid phosphorylation of Ser727 of Stat1/3 was
observed resulting from the signaling cascade PKCε-Raf1-
MEK1/2-ERK1/2 [10].
4. How may Stat3 be integrated into PGE2 signaling for
cardiac hypertrophy?
In the nucleus Stat3 stimulates the COX2 gene and COX2
protein expression, and the resulting increase in PGE2 levels
further stimulates expression of COX2 in a positive feedback
loop (Fig. 1). This feedback loop may not only operate in
paracrine or autocrine but also in the intracrine mode since
both COX2 and the PGE2 receptor EP4 locate primarily to
the nuclear envelope [3,5]. Stat3 is also known to enhance
expression of the angiotensinogen (Angtg) gene and
subsequent generation of AngII [11,12]. AngII induces the
release of the IL6-related cytokines (IL6, CT1, LIF), which,
in turn, activate the canonical JAK/Stat signaling cascade
leading to delayed tyrosine phosphorylation of Stat3, thus
establishing an autocrine/paracrine loop (Fig. 1). AngII-
induced hypertrophy is thought to primarily depend on the
activation of its Gq-coupled receptor (AT1). However, the
AT1 receptor is also able to activate several additional
downstream signaling molecules including the Src family
protein tyrosine kinases and ERK1/2 through G-protein-
independent mechanisms [13]. In particular, AT1 may
directly interact with JAK2, the SHP2 tyrosine phosphatase,
phospholipase-C (PLC), and other proteins serving as
signaling adapters and scaffold components. Furthermore,
both AT1 and EP4 are reported to transactivate the EGFR,
which may also signal via the ERK1/2 pathway (Fig. 1).
Thus, multiple signaling tracks join the MEK-ERK pathway,
Fig. 1. Simplified scheme of the major routes connected with PGE2
signaling. PGE2 is synthesized by enzymes on the nuclear envelope surface.
The PGE2 receptor subtype EP4 locates to the cell membrane and to the
nuclear envelope. The EP4 receptor is able to couple with either Gs or Gi
proteins; when coupling to Gi, the heterodimeric Gβ/γ component is
thought to activate the PI3K-PKB path [13]. The PI3K-dependent activation
of the MEK-ERK pathway is not yet defined in detail. Angtg is
intracellularly transformed to AngII before secretion. The AngII receptor
AT1 may signal via Gq as well as by direct interaction with several adapter
proteins including β-arrestin, Src, and JAK. Both EP4 and AT1 receptors
can transactivate the EGF receptor (a receptor tyrosine kinase=RTK).
ERK1/2 occurs in the cytosolic and nuclear fractions. The IL6-related
cytokines may be secreted and act in a paracrine and autocrine manner while
PGE2 may also act in an intracrine manner on the nuclear EP4 receptors. For
full transcriptional activation Stat3 requires phosphorylation at Tyr705 by
JAK and at Ser727 by ERK. Abbreviations are in the text except for: DAG,
diacylglycerol; GSK, glycogen synthase kinase; iNOS, inducible NO
synthase; PI3K, phosphoinositide 3-kinase.
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which emerges as the major communication route. Multi-
farious direct and indirect (involving de novo protein syn-
thesis) signaling loops connecting the PGE2-EP4, JAK/Stat,
and MEK-ERK systems may account for fast as well as
delayed activation by phosphorylation cascades. Despite
many advances in our understanding of the intracellular
signaling network, cardiac hypertrophy and heart failure
remain a formidable challenge since an effective causative
treatment strategy is still lacking.
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